MET and hepatocellular carcinoma: In a phase 2 trial of tivantinib as a single agent for the treatment of hepatocellular carcinoma (HCC), significant improvement in OS (7.2 months vs. 3.8 months, HR = 0.38, p = 0.01) was observed in patients with high tumor MET expression [65].